← Every company
Astellas Pharma Inc Patents
What Astellas Pharma Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ALPMY on carbonthat →Filings on file
47
Granted
4
Still pending
43
Filed under
4 names
47 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEINA61K 31/496, C07D 401/14, C07D 487/08, A61K 47/545, A61K 47/55, A61P 1/18, A61P 35/00, A61K 31/4995, A61K 31/513, A61K 31/517, A61K 31/519, C07D 405/14, C07D 417/14, C07D 471/04, C07D 487/10, C07D 519/00Filed as Astellas Pharma Inc.2026-05-26Tomohiro YOSHINARI | pending |
| Azacycloalkyl Carbonyl Cyclic Amine CompoundA61P 29/00, A61K 31/438, C07D 413/14, A61K 31/4545, A61K 31/506, A61K 31/5377, A61K 31/5386, C07D 209/52, C07D 401/06, C07D 401/14, C07D 417/14, C07D 453/02, C07D 453/06, C07D 471/08, C07D 491/044, C07D 491/107Filed as Astellas Pharma Inc.2026-03-20Takafumi SHIMIZU | pending |
| ANTI-B7-H3 DUAL PAYLOAD IMMUNOMODULATORY ANTIBODY DRUG CONJUGATESFiled as ASTELLAS PHARMA INC.2026-01-29MIAO WEN | pending |
| PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUNDA61K 47/55, A61P 35/00, A61K 31/517Filed as Astellas Pharma Inc.2025-12-19Asuka SAITO | pending |
| AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUNDA61P 29/00, A61K 31/438, C07D 413/14, A61K 31/4545, A61K 31/506, A61K 31/5377, A61K 31/5386, C07D 209/52, C07D 401/06, C07D 401/14, C07D 417/14, C07D 453/02, C07D 453/06, C07D 471/08, C07D 491/044, C07D 491/107Filed as Astellas Pharma Inc.2025-12-09Takafumi SHIMIZU | pending |
| METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTIONA01K 67/027, G01N 33/5088, A61P 9/10, A61P 43/00, A61P 9/00, A61P 25/00, A01K2207/10, A01K2227/106, A01K2267/03, A01K2267/0375, A61K 9/0019, A61K 9/0085, A61K 9/127, A61K 9/51, A61K 9/5123, A61K 9/5184, A61K 31/7088, A61K 31/7105, A61K 31/711, A61K 31/7115, A61K 35/76, A61K 35/761, A61K 38/17, A61K 38/1709, A61K 47/34, A61K 47/44, A61K 48/00, A61K 48/0041, A61K 48/005, C07D 211/58, C07K 14/435, C07K 14/47, C07K 14/4702, C07K 14/57536, C12N 15/864, C12N 15/8645, C12N 15/867, C12N2750/14132, C12N2750/14143, C12Q 1/02, G01N 33/15, G01N 33/48, G01N2500/10, A61K2300/00Filed as ASTELLAS PHARMA INC.2025-11-11Soichiro NAKAHARA | pending |
| METHOD FOR PRODUCING GROUP 2 INNATE LYMPHOID CELLSA61K 35/14, C12N 5/0634, C12N 9/12, A61P 37/02, A61P 33/14, A61P 37/08, A61P 29/00, A61K 35/545, C07K 14/5428, C07K 14/55, C12N 5/06, C12N 5/0635, C12N 5/0636, C12N 5/0647, C12N 5/10, C12N2501/2302, C12N2501/2333, C12N2501/727, C12N2506/11, C12N2506/45, C12Y 207/11022Filed as Astellas Pharma Inc.2025-10-17Shin KANEKO | pending |
| CELL SEEDING METHODFiled as ASTELLAS PHARMA INC.2025-09-08Miho SASAMATA | pending |
| CARBAMOYL LIPID OR UREA LIPID EACH HAVING CYCLIC AMINE, LIPID NANOPARTICLES CONTAINING SAME, AND PHARMACEUTICAL COMPOSITIONA61K 9/1271, A61K 9/5123, A61K 31/7105, A61K 38/185, C07D 211/22, C07D 243/08, C12N 15/88Filed as Astellas Pharma Inc.2025-07-29Takahiro NIGAWARA | pending |
| QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEINA61P 35/00, C07D 487/08, A61K 31/517, C07D 519/00Filed as Astellas Pharma Inc.2025-07-14Tomohiro YOSHINARI | pending |
| 4-AMINOPIPERIDINE COMPOUND, LIPID NANOPARTICLES THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEC07D 211/58, A61K 9/5123, A61K 9/5146, A61K 38/1709, A61K 48/0041, A61K 48/005Filed as Astellas Pharma Inc.2025-06-24Hitoshi FUMIYAMA | pending |
| Combination of Talazoparib and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate CancerA61K 31/4166, A61K 31/5025, A61P 35/04, A61P 35/00, A61K 45/06, A61K2300/00Filed as Astellas Pharma Inc.2025-06-16Maria Teresa Koehler | pending |
| ENGINEERED NATURAL KILLER CELLS AND RELATED METHODSC12N 5/0646, A61P 35/00, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/35, A61K 40/30, A61K 40/15, A61K 35/17, A61K 35/545, A61K 38/2013, A61K 38/2086, A61K 39/395, A61K 39/3955, A61K2039/505, C07K 14/70539, C07K 16/2803, C12N2501/125, C12N2501/2303, C12N2501/2307, C12N2501/2315, C12N2501/2318, C12N2501/2321, C12N2501/26, C12N2501/999, C12N2506/02, C12N2506/03, C12N2506/45, C12N2510/00, A61K2300/00Filed as ASTELLAS PHARMA INC.2025-06-12Kim CLARY | pending |
| STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATESFiled as ASTELLAS PHARMA INC.2025-05-29GANG YIN | pending |
| COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 IMMUNE CHECKPOINT INHIBITORSC07K 16/2809, A61P 35/00, A61K2039/505, C07K 16/28, C07K 16/2818, C07K 16/2827, C07K2317/31Filed as ASTELLAS PHARMA EUROPE BV2025-05-20Aya KIKUCHI | pending |
| ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUNDA61K 47/6803, A61K 47/6889, A61K 47/6849Filed as ASTELLAS PHARMA INC.2025-05-15Michinori AKAIWA | pending |
| ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOFA61K 9/2009, A61P 43/00, A61K 9/1611Filed as ASTELLAS PHARMA INC.2025-04-25Peter GRUBER | pending |
| USE OF ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENTC07K 16/28, A61P 35/00, A61K2039/507, C07K 16/2818, C07K 16/2878, C07K2317/24, C07K2317/31, C07K2317/52, C07K2317/622Filed as Astellas Pharma Inc.2025-04-17Masahito SATO | pending |
| COMPOSITION FOR NEAR INFRARED LYMPHATIC IMAGING AND USES AND DOSAGES THEREFORA61K 49/0032, A61K 49/0054, A61K2123/00Filed as ASTELLAS PHARMA INC.2025-04-14Sadaaki Kimura | pending |
| Combination of Talazoparib and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate CancerA61P 35/00, A61K 31/5025, A61P 35/04, A61K 31/4166, A61K 45/06, A61K2300/00Filed as Astellas Pharma Inc.2025-04-01Akos Gabor Czibere | pending |
| Combination TherapyA61K 31/4439, A61P 35/04, A61P 35/00, A61K 45/06, A61K2300/00Filed as Astellas Pharma Inc.2025-03-04Jacqueline Gibbons | pending |
| ANTI CANCER COMBINATIONS COMPRISING TARGETED THERAPYA61K 31/517, A61P 35/00, A61K 31/436, A61K 31/4439, A61K 31/497, A61K 31/519, A61K 31/5377, A61K 31/55, A61K 39/3955Filed as Astellas Pharma Inc.2025-02-11Takeyuki NAGASHIMA | pending |
| ANTI CANCER COMBINATIONS COMPRISING CHEMOTHERAPYA61K 31/517, A61P 35/00, A61K 31/337, A61K 31/4745, A61K 31/513, A61K 31/555, A61K 31/7068Filed as Astellas Pharma Inc.2025-02-11Takeyuki NAGASHIMA | pending |
| HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEINA61P 35/00, C07D 487/10, A61P 43/00, A61P 35/04, A61K 31/496, A61K 31/513, A61K 31/517, A61K 31/5377, C07D 401/14, C07D 403/14, C07D 405/14, C07D 413/14, C07D 471/10Filed as Astellas Pharma Inc.2025-02-07Takahiro MORIKAWA | pending |
| HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEINC07D 413/14, A61K 47/55, A61P 35/00, A61K 31/4709, A61K 31/517, A61K 31/5377, C07D 401/14, C07D 403/14, C07D 405/14, C07D 417/14Filed as Astellas Pharma Inc.2025-02-05Takahiro MORIKAWA | pending |
| ANTI-B7-H3 DUAL PAYLOAD IMMUNOMODULATORY ANTIBODY DRUG CONJUGATESFiled as ASTELLAS PHARMA INC.2025-01-29Miao Wen | pending |
| HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEINA61P 1/18, C07D 405/14, A61P 43/00, A61P 35/00, A61K 31/496, A61K 31/517, A61K 31/519, A61K 31/551, C07D 205/04, C07D 401/14, C07D 403/06, C07D 403/10, C07D 403/14, C07D 471/04, C07D 487/08, C07D 519/00Filed as ASTELLAS PHARMA INC.2024-12-31Tomohiro YOSHINARI | pending |
| METHODS FOR TREATING PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS USING A DGK ZETA INHIBITORA61K 31/501, A61P 35/00Filed as ASTELLAS PHARMA INC.2024-12-17Masaomi TAKIZAWA | pending |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-INTEGRIN ALPHA11 ANTIBODY FOR TREATMENT OR PREVENTION OF AGING-RELATED DISEASESC07K 16/2839, C07K 16/2842, A61P 43/00, A61P 37/06, A61P 3/10, A61P 13/12, A61P 3/12, A61K2039/505, C07K2317/565, C07K2317/732Filed as Astellas Pharma Inc.2024-12-06Hiroshi UCHINO | pending |
| AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUNDA61P 29/00, A61K 31/438, C07D 413/14, A61K 31/4545, A61K 31/506, A61K 31/5377, A61K 31/5386, C07D 209/52, C07D 401/06, C07D 401/14, C07D 417/14, C07D 453/02, C07D 453/06, C07D 471/08, C07D 491/044, C07D 491/107Filed as Astellas Pharma Inc.2024-12-05Takafumi SHIMIZU | 12522593 |
| ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODYC07K 16/2809, C07K 16/2878, C07K 16/30, A61P 35/02, A61P 35/00, A61K2039/505, C07K 16/28, C07K 16/2827, C07K 16/2896, C07K2317/31, C07K2317/53, C07K2317/55, C07K2317/56, C07K2317/622, C07K2317/73, C07K2317/732, C07K2317/734, C07K2317/74, C07K2317/92, C07K2317/94Filed as Astellas Pharma Inc.2024-11-08Shinji SOGA | pending |
| ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUNDA61K 47/6803, A61K 47/6889, A61K 47/6849Filed as ASTELLAS PHARMA INC.2024-09-25Michinori AKAIWA | 12390536 |
| HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEINC07D 403/14, C07D 417/14, C07D 487/08, A61P 1/18, A61P 35/00, A61K 31/4709, A61K 31/4995, A61K 31/517, A61K 31/519, C07D 401/12, C07D 401/14, C07D 405/14, C07D 407/14, C07D 413/14, C07D 471/04, C07D 487/04, C07D 519/00Filed as Astellas Pharma Inc.2024-09-10Tomohiro YOSHINARI | pending |
| Combination TherapyFiled as Astellas Pharma Inc.2024-08-19Jacqueline Gibbons | pending |
| PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEXA61K 47/6803, A61K 47/10, A61K 47/26, A61K 51/0446, A61K 51/1051, A61K 51/1093, C07K 16/3007, C07K 16/3092, C07K2317/55, C07K2317/71Filed as Astellas Pharma Inc.2024-07-05Jumpei Suemitsu | pending |
| PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUNDA61K 47/55, A61K 31/517, C07D 487/08, A61P 1/00, A61P 35/00, A61K 31/695Filed as Astellas Pharma Inc.2024-06-24Takeyuki NAGASHIMA | pending |
| SUBSTITUTED QUINOLINE DERIVATIVEA61P 21/00, C07D 401/12, A61P 21/04, A61K 31/40, A61K 31/4375, A61K 31/4545, A61K 31/4709, A61K 31/496, A61K 31/5377, C07D 207/48, C07D 215/20, C07D 215/48, C07D 401/14, C07D 413/14, C07D 471/04, C07D 487/10, C07D 519/00Filed as ASTELLAS PHARMA INC.2024-06-21Ryuichi SEKIOKA | pending |
| STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATESFiled as ASTELLAS PHARMA2024-05-30Gang YIN | pending |
| INDOCYANINE COMPOUND-CONTAINING SOLID PHARMACEUTICAL COMPOSITIONA61K 49/0034, A61K 9/19, A61K 47/12, A61K 47/26, A61K 49/0054Filed as ASTELLAS PHARMA INC.2024-05-16Satomi Ikeuchi | pending |
| METHODS OF REDUCING LIKELIHOOD OF DEVELOPING POST-OPERATIVE ATRIAL FIBRILLATIONFiled as ASTELLAS PHARMA INC.2024-03-28OLIVIER VAN TILL | pending |
| PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEA61K 31/426, A61K 47/32, A61P 13/08, A61P 3/08, A61P 3/04, A61P 3/06, A61P 3/10, A61P 13/10, A61K 9/06, A61K 9/2009, A61K 9/2013, A61K 9/2031, A61K 9/2054, A61K 9/2095, A61K 9/2853, A61K 9/2866, A61K 47/34, A61K 47/38Filed as ASTELLAS PHARMA INC.2024-03-22YUUKI TAKAISHI | 12059409 |
| PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEA61K 31/426, A61K 9/0004, A61K 9/1652, A61K 9/2031, A61K 9/205, A61K 9/2054, A61K 9/2072, A61K 9/2086, A61K 9/2846, A61K 9/2866, A61K 47/36Filed as ASTELLAS PHARMA INC.2024-03-22YUUKI TAKAISHI | 12097189 |
| HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEINA61K 31/496, C07D 401/14, C07D 487/08, A61K 47/545, A61K 47/55, A61P 1/18, A61P 35/00, A61K 31/4995, A61K 31/513, A61K 31/517, A61K 31/519, C07D 405/14, C07D 417/14, C07D 471/04, C07D 487/10, C07D 519/00Filed as Astellas Pharma Inc.2024-02-20Tomohiro YOSHINARI | pending |
| PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEFiled as ASTELLAS PHARMA INC.2024-02-09YUUKI TAKAISHI | pending |
| Combination TherapyFiled as Astellas Pharma Inc.2024-02-06Jacqueline Gibbons | pending |
| A PHARMACEUTICAL COMPOSITION FOR IMAGINGA61K 49/0034, A61K 49/0054Filed as ASTELLAS PHARMA INC.2024-01-23Masako Saito | pending |
| GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNAC12N 15/113, C12N 9/78, C12N2310/11, C12N2750/14143, C12Y 305/04Filed as ASTELLAS PHARMA INC.2024-01-19Takatomo ARAI | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.